Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2023-06-30
Product name:
NAT-SUNITINIB
DIN:
02539284
Product Monograph/Veterinary Labelling:
Date:
2023-06-29
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
NATCO PHARMA (CANADA) INC
2000 Argentia Road, Plaza 1, Suite 200
Mississauga
Ontario
Canada
L5N 1P7
Class:
Human
Dosage form(s):
Capsule
Route(s) of administration:
Oral
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
10:00.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
L01EX01 SUNITINIB
Active ingredient group (AIG) number:See footnote5
0151642003
| Active ingredient(s) | Strength |
|---|---|
| SUNITINIB (SUNITINIB MALATE) | 50 MG |